A single-arm, open-label, phase 2 study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer (NSCLC)

被引：2
|
作者：
Socinski, M. [1 ]
Gil, M. [2 ]
Shahidi, J. [3 ]
Chao, G. Y. [4 ]
Villaruz, L. [1 ]
机构：
[1] Univ Pittsburgh, Med Oncol, UPMC Canc Pavil, Pittsburgh, PA USA
[2] Eli Lilly Polska, Oncol, Warsaw, Poland
[3] Eli Lilly & Co, Oncol, Indianapolis, IN 46285 USA
[4] Eli Lilly & Co, Biostat, Indianapolis, IN 46285 USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw383.98
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1298TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Study of three weekly nab-paclitaxel regimens in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC)
    Hawkins, M. J.
    Manikhas, G.
    Makhson, A.
    Cheporov, S.
    Orlov, S.
    Yablonsky, P.
    Bhar, P.
    Socinski, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion
    Tamiya, Motohiro
    Tamiya, Akihiro
    Suzuki, Hidekazu
    Taniguchi, Yoshihiko
    Katayama, Kanako
    Minomo, Shojiro
    Nakao, Keiko
    Takeuchi, Naoko
    Matsuda, Yoshinobu
    Naito, Yujiro
    Shiroyama, Takayuki
    Okamoto, Norio
    Okishio, Kyoichi
    Kumagai, Toru
    Atagi, Shinji
    Imamura, Fumio
    Hirashima, Tomonori
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (04) : 1106 - 1112
  • [23] A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non-Small-Cell Lung Cancer
    Camidge, D. Ross
    Berge, Eamon M.
    Doebele, Robert C.
    Ballas, Marc S.
    Jahan, Thierry
    Haigentz, Missak, Jr.
    Hoffman, David
    Spicer, James
    West, Howard
    Lee, Pablo
    Yang, Ling
    Joshi, Adarsh
    Gao, Ling
    Yurasov, Sergey
    Mita, Alain
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (10) : 1532 - 1539
  • [24] Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial
    Chang, Zhiwei
    Liu, Xiao-Lei
    Yu, Dan-Dan
    Han, Hui-Qiong
    He, Jian
    Wang, Rui-Rui
    Qin, Yan-ru
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 340 - 340
  • [25] Safety and efficacy phase 2 study of nab-paclitaxel maintenance treatment after nabpaclitaxel plus carboplatin in stage IIIB/IV non-small cell lung cancer
    Nakao, A.
    Uchino, J.
    Nagata, N.
    Takayama, K.
    Watanabe, K.
    Fujita, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S103 - S103
  • [26] nab-paclitaxel plus carboplatin induction followed by nab-paclitaxel maintenance in squamous non-small cell lung cancer (NSCLC): Results from the ABOUND. sqm study
    Spigel, D. R.
    Jotte, R. M.
    Ponce Aix, S.
    Gressot, L.
    Morgensztern, D.
    McCleod, M.
    Socinski, M. A.
    Daniel, D.
    Juan-Vidal, O.
    Kim, E. S.
    West, H. J.
    Chen, T.
    Bhore, R.
    Ong, T. J.
    Gridelli, C.
    Thomas, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [27] Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
    West, Howard
    McCleod, Michael
    Hussein, Maen
    Morabito, Alessandro
    Rittmeyer, Achim
    Conter, Henry J.
    Kopp, Hans-Georg
    Daniel, Davey
    McCune, Steven
    Mekhail, Tarek
    Zer, Alona
    Reinmuth, Niels
    Sadiq, Ahad
    Sandler, Alan
    Lin, Wei
    Lohmann, Tania Ochi
    Archer, Venice
    Wang, Lijia
    Kowanetz, Marcin
    Cappuzzo, Federico
    LANCET ONCOLOGY, 2019, 20 (07): : 924 - 937
  • [28] Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase lb and randomized, open-label, multicenter, phase 2 trial in Japan
    Watanabe, Satoshi
    Yoshioka, Hiroshige
    Sakai, Hiroshi
    Hotta, Katsuyuki
    Takenoyama, Mitsuhiro
    Yamada, Kazuhiko
    Sugawara, Shunichi
    Takiguchi, Yuichi
    Hosomi, Yukio
    Tomii, Keisuke
    Niho, Seiji
    Yamamoto, Nobuyuki
    Nishio, Makoto
    Ohe, Yuichiro
    Kato, Terufumi
    Takahashi, Toshiaki
    Kamada, Ami
    Suzukawa, Kazumi
    Omori, Yukie
    Enatsu, Sotaro
    Nakagawa, Kazuhiko
    Tamura, Tomohide
    LUNG CANCER, 2019, 129 : 55 - 62
  • [29] A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancer
    Liu, Zhefeng
    Wei, Zhimin
    Hu, Yi
    Gao, Feng
    Hao, Lu
    Fang, Ping
    Sun, Shengjie
    Li, Jinyu
    Jiao, Shunchang
    MEDICAL ONCOLOGY, 2015, 32 (08)
  • [30] Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study
    Paz-Ares, Luis
    Mezger, Joerg
    Ciuleanu, Tudor E.
    Fischer, Juergen R.
    von Pawel, Joachim
    Provencio, Mariano
    Kazarnowicz, Andrzej
    Losonczy, Gyoergy
    de Castro, Gilberto, Jr.
    Szczesna, Aleksandra
    Crino, Lucio
    Reck, Martin
    Ramlau, Rodryg
    Ulsperger, Ernst
    Schumann, Christian
    Miziara, Jose Elias A.
    Lessa, Alvaro E.
    Dediu, Mircea
    Balint, Beatrix
    Depenbrock, Henrik
    Soldatenkova, Victoria
    Kurek, Raffael
    Hirsch, Fred R.
    Thatcher, Nick
    Socinski, Mark A.
    LANCET ONCOLOGY, 2015, 16 (03): : 328 - 337
12345